177 related articles for article (PubMed ID: 33576256)
1. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
2. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
3. A review of neurotoxicities associated with immunotherapy and a framework for evaluation.
Burton LB; Eskian M; Guidon AC; Reynolds KL
Neurooncol Adv; 2021 Nov; 3(Suppl 5):v108-v120. PubMed ID: 34859238
[TBL] [Abstract][Full Text] [Related]
4. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
5. Neurologic complications of immune checkpoint inhibitors.
Haugh AM; Probasco JC; Johnson DB
Expert Opin Drug Saf; 2020 Apr; 19(4):479-488. PubMed ID: 32126176
[No Abstract] [Full Text] [Related]
6. Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors.
Mok K; Wu C; Chan S; Wong G; Wong VW; Ma B; Lui R
Clin Colorectal Cancer; 2024 Mar; 23(1):4-13. PubMed ID: 38172003
[TBL] [Abstract][Full Text] [Related]
7. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Ertl C; Ruf T; Mentzer D; Kong M; Kramer R; Bergwelt-Baildon MV; Subklewe M; Tomsitz D; Ascierto PA; Dummer R; Gogas H; Lebbé C; Long GV; McArthur G; Neilan TG; Ribas A; Robert C; Schadendorf D; Zimmer L; Eigentler T; Grabbe S; Forschner A; Kähler KC; Milani V; Pföhler C; Hassel J; Gutzmer R; Loquai C; Routy B; Furness AJS; Blank C; Wolchok JD; French LE; Hauschild A; Heinzerling L
Eur J Cancer; 2024 Mar; 199():113505. PubMed ID: 38262306
[TBL] [Abstract][Full Text] [Related]
8. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
Kovac MB; Seruga B
Radiol Oncol; 2024 Apr; ():. PubMed ID: 38613842
[TBL] [Abstract][Full Text] [Related]
9. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
Khan S; Gerber DE
Semin Cancer Biol; 2020 Aug; 64():93-101. PubMed ID: 31330185
[TBL] [Abstract][Full Text] [Related]
10. Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer.
Tanaka T; Taoka M; Makimoto G; Ninomiya K; Higo H; Fujii M; Ichihara E; Ohashi K; Hotta K; Tabata M; Maeda Y
Intern Med; 2024 May; 63(9):1261-1267. PubMed ID: 37722894
[TBL] [Abstract][Full Text] [Related]
11. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
Kroschinsky F; Stölzel F; von Bonin S; Beutel G; Kochanek M; Kiehl M; Schellongowski P;
Crit Care; 2017 Apr; 21(1):89. PubMed ID: 28407743
[TBL] [Abstract][Full Text] [Related]
12. Impact of diagnostic investigations in the management of CAR T-cell-associated neurotoxicity.
Mauget M; Lemercier S; Quelven Q; Maamar A; Lhomme F; De Guibert S; Houot R; Manson G
Blood Adv; 2024 May; 8(10):2491-2498. PubMed ID: 38501964
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Use in Patients With Lung Cancer and Comorbidities.
von Itzstein MS; Gonugunta AS; Mayo HG; Minna JD; Gerber DE
Cancer J; 2020; 26(6):525-536. PubMed ID: 33298724
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic Agents for Intratumoral Immunotherapy.
Shyr CR; Liu LC; Chien HS; Huang CP
Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006049
[TBL] [Abstract][Full Text] [Related]
15. The need for ambulatory emergency oncology: exemplified by the management of immune checkpoint inhibitor toxicity.
Cooksley T; Klotz A; Marshall E; Weaver J; Font C; Lasserson D
Support Care Cancer; 2023 Oct; 31(12):653. PubMed ID: 37878140
[TBL] [Abstract][Full Text] [Related]
16. Neurologic Complications of Cancer Immunotherapy.
Wang N
Continuum (Minneap Minn); 2023 Dec; 29(6):1827-1843. PubMed ID: 38085900
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department.
Yeung SJ; Qdaisat A; Chaftari P; Lipe D; Merlin J; Rajha E; Wechsler A; Sandoval M; Viets J; Al-Breiki A; Shah M; Pandey R; Kamal M; Khattab O; Toale K; Wattana M; Elsayem A; Gaeta S; Brock P; Reyes-Gibby C; Alagappan K
J Am Coll Emerg Physicians Open; 2020 Dec; 1(6):1637-1659. PubMed ID: 33392573
[TBL] [Abstract][Full Text] [Related]
18. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients - A case report and review of the literature.
Zhang Y; Wen X; OuYang Y; Hu Y; Fang X; Zhang J; Yuan Y
Heliyon; 2024 Jan; 10(2):e24380. PubMed ID: 38293388
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi).
Reyes-Gibby CC; Caterino JM; Coyne CJ; Kyriacou DN; Qdaisat A; McQuade J; Owen DH; Bischof JJ; Shete S; Yeung SJ
Emerg Cancer Care; 2024; 3(1):. PubMed ID: 38725994
[TBL] [Abstract][Full Text] [Related]
20. Availability of antidotes in the primary care emergency centers of Catalonia.
Aguilar Salmerón R; Gispert Ametller MÀ; Jambrina Albiach AM; Martínez Sánchez L; Fernández de Gamarra Martínez E; Santomà I Cardús À
Emergencias; 2024 Jan; 36(1):75-78. PubMed ID: 38318746
[No Abstract] [Full Text] [Related]
[Next] [New Search]
